Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties

J Am Coll Cardiol. 2005 Mar 1;45(5):668-76. doi: 10.1016/j.jacc.2004.11.042.

Abstract

Objectives: We hypothesized that some aspects of left ventricular assist device (LVAD) reverse remodeling could be independent of hemodynamic factors and would primarily depend upon normalization of neurohormonal milieu.

Background: The relative contributions of LVAD-induced hemodynamic unloading (provided to the left ventricle [LV]) and normalized neurohormonal milieu (provided to LV and right ventricle [RV]) to reverse remodeling are not understood.

Methods: Structural and functional characteristics were measured from hearts of 65 medically managed transplant patients (MED), 30 patients supported with an LVAD, and 5 nonfailing donor hearts not suitable for transplantation.

Results: Compared with MED patients, diastolic pulmonary pressures trended lower (p < 0.01) and cardiac output higher (p < 0.001) in LVAD patients; V(30) (ex vivo ventricular volume yielding 30 mm Hg, an index of ventricular size) in LVAD patients was decreased in the LV (p < 0.05) but did not change significantly in RV. The LVAD support improved force generation in response to beta-adrenergic stimulation in isolated LV (increase in developed force from 6.3 +/- 0.6 to 18.5 +/- 4.4 mN/m(2), p < 0.01) and RV (increase in developed force, from 10.9 +/- 2.0 to 20.5 +/- 3.1 mN/m(2), p < 0.05) trabeculae. The LVAD patients had higher myocardial beta-adrenergic receptor density in LV (p < 0.01) and RV (p < 0.01). Protein kinase A (PKA) hyperphosphorylation of the ryanodine receptor 2 (RyR2)/calcium release channel was significantly reduced by LVAD in both RV and LV (p < 0.01).

Conclusions: Improved beta-adrenergic responsiveness, normalization of the RyR2 PKA phosphorylation, and increased beta-adrenergic receptor density in LV and RV after LVAD support suggest a primary role of neurohormonal environment in determining reverse remodeling of the beta-adrenergic pathway.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Cardiomyopathy, Dilated / complications
  • Cardiomyopathy, Dilated / physiopathology
  • Cyclic AMP-Dependent Protein Kinases / physiology
  • Female
  • Heart Failure / physiopathology
  • Heart Failure / therapy
  • Heart Transplantation
  • Heart-Assist Devices*
  • Hemodynamics / physiology
  • Humans
  • In Vitro Techniques
  • Male
  • Middle Aged
  • Myocardial Contraction / physiology
  • Myocardial Ischemia / complications
  • Myocardial Ischemia / physiopathology
  • Phosphorylation
  • Receptors, Adrenergic, beta / physiology*
  • Ryanodine Receptor Calcium Release Channel / physiology
  • Tissue Donors
  • Treatment Outcome
  • Ventricular Dysfunction, Left / physiopathology
  • Ventricular Dysfunction, Left / therapy*
  • Ventricular Dysfunction, Right / physiopathology
  • Ventricular Dysfunction, Right / therapy*

Substances

  • Receptors, Adrenergic, beta
  • Ryanodine Receptor Calcium Release Channel
  • Cyclic AMP-Dependent Protein Kinases